

COVID19 vaccine type and humoral immune response in patients receiving dialysis

Table of Contents

| | |
|---|-----------|
| Supplemental Methods | p2 |
| Supplemental Table 1 Characteristics of patients on dialysis by vaccine type | p3 |

Supplemental Methods

Assay Characteristics

The Siemens total RBD Ig assay measures IgG and IgM antibodies. This assay is reported by the manufacture to have 100% sensitivity and 99.8% specificity for tests performed ≥ 14 days after a positive reverse transcriptase polymerase chain reaction test¹; it has been validated independently with similar performance characteristics^{2, 3}. We used one of two Siemens RBD IgG assays, which are semiquantitative two-step sandwich indirect chemiluminescent assay with a manufacturer reported 95.6% (95% CI: 92.2-97.8%) sensitivity and 99.9% (95% CI 99.6-99.9%) specificity for tests performed ≥ 21 days post positive reverse transcriptase polymerase chain reaction test. An index value ≥ 1.0 is considered reactive. The two assays are compatible using a conversion factor, but one has a larger maximal index value range (>44 versus > 150).

We classified responses as absent total RBD Ig antibody, absent semiquantitative IgG antibody (index value < 1), diminished antibody (semiquantitative IgG index value < 10), or medium to high antibody (≥ 10)⁴. We chose index value ≥ 10 as a cut-point based on a Siemens study (n=74) evaluating correlation with plaque reduction neutralization test which reported index values ≥ 10 had a positive predictive value of 100% for plaque reduction neutralization test⁵ $> 1:80$.

REFERENCES

1. U.S. Food & Drug Administration. *EUA Authorized Serology Test Performance*. 2020. Accessed June 28, 2021. <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance>
2. Schnurra C, Reiners N, Biemann R, Kaiser T, Trawinski H, Jassoy C. Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests. *J Clin Virol*. Aug 2020;129:104544. doi:10.1016/j.jcv.2020.104544
3. Public Health England. *Evaluation of sensitivity and specificity of 4 commercially available SARS-CoV-2 antibody immunoassays*. . 2020. Accessed June 6, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/898437/Evaluation_of_sensitivity_and_specificity_of_4_commercially_available_SARS-CoV-2_antibody_immunoassays.pdf
4. Anand S, Montez-Rath ME, Han J, et al. Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis. *Ann Intern Med*. May 18 2021;doi:10.7326/M21-0256

Supplemental Table 1 Characteristics of patients on dialysis by vaccine type

| | Overall | mRNA1273 | BNT162b2 | Ad26.COV2.S |
|---|-----------|-----------|----------|-------------|
| Patient characteristics | N=2099 | N=1316 | N=416 | N=367 |
| Age | | | | |
| 18-44 | 180 (8) | 87 (7) | 36 (9) | 57 (16) |
| 45-64 | 685 (33) | 365 (28) | 106 (25) | 214 (58) |
| 65-79 | 885 (42) | 606 (46) | 195 (47) | 84 (23) |
| ≥80 | 349 (17) | 258 (20) | 79 (19) | 12 (3) |
| Gender | | | | |
| M | 1277 (61) | 792 (60) | 264 (63) | 221 (60) |
| F | 822 (39) | 524 (40) | 152 (37) | 146 (40) |
| Race and Ethnicity | | | | |
| Hispanic | 721 (34) | 406 (31) | 165 (40) | 150 (41) |
| Non-Hispanic white | 522 (25) | 316 (24) | 109 (26) | 97 (26) |
| Non-Hispanic Black | 209 (10) | 81 (6) | 28 (7) | 100 (27) |
| Asian | 312 (15) | 263 (20) | 42 (10) | 7 (2) |
| Other | 61 (3) | 49 (4) | 9 (2) | 3 (1) |
| Missing | 274 (13) | 201 (15) | 63 (15) | 10 (3) |
| Geographic region | | | | |
| South | 464 (22) | 73 (6) | 38 (9) | 353 (96) |
| West | 1635 (78) | 1243 (94) | 378 (91) | 14 (4) |
| Dialysis Modality | | | | |
| Hemodialysis | 1176 (84) | 1111 (85) | 354 (85) | 311 (85) |
| CCPD | 266 (13) | 176 (13) | 49 (12) | 41 (11) |
| CAPD | 25 (1) | 18 (1) | 2 (1) | 5 (1) |
| Home Hemodialysis | 32 (2) | 11 (1) | 11 (2) | 10 (3) |
| ESKD Vintage (years) | | | | |
| < 2 | 799 (38) | 506 (38) | 173 (42) | 120 (33) |
| 2 – 5 | 726 (35) | 455 (35) | 143 (34) | 128 (35) |
| ≥ 5 | 574 (27) | 355 (27) | 100 (24) | 119 (32) |
| Diabetes | | | | |
| Yes | 1350 (64) | 848 (64) | 258 (62) | 244 (66) |
| No | 749 (36) | 464 (36) | 158 (38) | 123 (34) |
| RBD antibody status prior to vaccine[^] | | | | |
| Seropositive | 696 (33) | 361 (27) | 141 (34) | 194 (53) |
| Seronegative | 1403 (67) | 955 (73) | 275 (66) | 173 (47) |

Abbreviations: CCPD, continuous cycloer-assisted peritoneal dialysis; CAPD, continuous automated peritoneal dialysis; ESKD, end-stage kidney disease; RBD, receptor-binding domain;

[^]seropositive prior to vaccination indicates likely SARS-CoV-2 infection prior to vaccination